Stocktoria
Pacira BioSciences, Inc. PCRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2011-02-03
Pacira BioSciences, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $726.4M | $701.0M | $675.0M | $666.8M | $541.5M |
| R&D expense | $117.3M | $81.6M | $76.3M | $84.8M | $55.5M |
| SG&A expense | $368.8M | $294.1M | $269.4M | $254.5M | $199.3M |
| Operating income | $19.2M | -$73.4M | $87.7M | $60.0M | $89.9M |
| Interest expense | — | — | $20.3M | $40.0M | $31.8M |
| Income tax | $9.8M | $36.5M | $19.7M | -$2.6M | $14.4M |
| Net income | $7.0M | -$99.6M | $42.0M | $15.9M | $42.0M |
| EPS (diluted) | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 |
| Operating cash flow | $152.0M | $189.4M | $154.6M | $145.3M | $125.7M |
| Free cash flow | $136.7M | $178.8M | $139.5M | $115.2M | $79.9M |
| Cash & equivalents | $158.5M | $276.8M | $153.3M | $104.1M | $585.6M |
| Inventory | $152.9M | $125.3M | $104.4M | $96.1M | $98.5M |
| Total assets | $1.3B | $1.6B | $1.6B | $1.7B | $2.1B |
| Total liabilities | $571.8M | $775.2M | $704.3M | $906.2M | $1.3B |
| Shareholders' equity | $693.1M | $778.3M | $870.1M | $775.0M | $730.4M |
Source: SEC EDGAR filings · CIK 0001396814 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.